Abstract
The toxicological relevance of effects observed at molecular stage, which occur at dose levels well below classical no-observed adverse effect levels is currently subject to controversial scientific debate. While the importance of molecular effects for the identification of a mode of action or an adverse outcome pathway is undisputed, their impact for other regulatory purposes remains uncertain. Here, we report the results of a 28-day rat-feeding study including three widely used hepatotoxic (tri)azole fungicides (cyproconazole, epoxiconazole and prochloraz) administered individually at five dose levels, ranging from slightly above the reference values to a clear toxic effect dose. Parameters analysed included pathology, histopathology, clinical chemistry and particularly effects on the molecular level. Since azole fungicides are considered to cause liver toxicity by a mechanism involving the constitutive androstane receptor (CAR), a known CAR activator (phenobarbital, PB) was administered to investigate potential similarities between triazoles and PB-mediated liver toxicity by pathway-focused gene expression analysis. Our results show an increase in liver weights and additionally histopathological changes (hepatocellular hypertrophy) for all substances at the top dose levels. The effects on liver weight were most pronounced for cyproconazole by which also the animals receiving the next lower dose were affected. In addition, vacuolisation of hepatocytes was observed at the top dose level. No such findings were obtained with any substance at lower doses to which consumers and operators might be exposed to. In contrast, the expression of sensitive marker genes (like some cytochrome-P-450 isoforms) was significantly affected also at the lower dose levels. While some of these changes, like the induction of genes related to fatty acid and phospholipid metabolism (e.g. Fasn, Fat/Cd36, Ppargc1a) or xenobiotic metabolism (Cyp1a1, Cyp2b1, Cyp3a2), could be associated with high dose effects like hepatocellular vacuolisation or hypertrophy, a histopathological correlate was lacking for others.
Similar content being viewed by others
References
Amaral JD, Xavier JM, Steer CJ, Rodrigues CM (2010) The role of p53 in apoptosis. Discov Med 9:145–152
Beausoleil C, Ormsby JN, Gies A, Hass U, Heindel JJ, Holmer ML, Nielsen PJ, Munn S, Schoenfelder G (2013) Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary. Chemosphere 93:847–856
Boobis AR, Doe JE, Heinrich-Hirsch B, Meek ME, Munn S, Ruchirawat M, Schlatter J, Seed J, Vickers C (2008) IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 38:87–96
OECD (2008) Repeated dose 28-day oral toxicity study in rodents. OECD, OECD Guideline For The Testing Of Chemicals, Paris
Currie RA, Peffer RC, Goetz AK, Omiecinski CJ, Goodman JI (2014) Phenobarbital and propiconazole toxicogenomic profiles in mice show major similarities consistent with the key role that constitutive androstane receptor (CAR) activation plays in their mode of action. Toxicology
Dewhurst I, Dellarco V (2004) Propiconazole. Joint WHO/FAO meeting on pesticide residues. Pesticide Residues in Food Evaluations Part II Toxicological Evaluation
Edwards SG, Godley NP (2010) Reduction of Fusarium head blight and deoxynivalenol in wheat with early fungicide applications of prothioconazole. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 27:629–635
EFSA (2008a) Conclusion on the peer review of epoxiconazole. EFSA Scientific Report 138:1–80
EFSA (2008b) Conclusion on the peer review of the pesticide risk assessment of the active substance tebuconazole. EFSA Scientific Report 176:1–109
Goetz AK, Dix DJ (2009a) Mode of action for reproductive and hepatic toxicity inferred from a genomic study of triazole antifungals. Toxicol Sci 110:449–462
Goetz AK, Dix DJ (2009b) Toxicogenomic effects common to triazole antifungals and conserved between rats and humans. Toxicol Appl Pharmacol 238:80–89
Goetz AK, Bao W, Ren H, Schmid JE, Tully DB, Wood C, Rockett JC, Narotsky MG, Sun G, Lambert GR, Thai SF, Wolf DC, Nesnow S, Dix DJ (2006) Gene expression profiling in the liver of CD-1 mice to characterize the hepatotoxicity of triazole fungicides. Toxicol Appl Pharmacol 215:274–284. doi:10.1016/j.taap.2006.02.016
Goetz AK, Rockett JC, Ren H, Thillainadarajah I, Dix DJ (2009) Inhibition of rat and human steroidogenesis by triazole antifungals. Syst Biol Reprod Med 55:214–226
Handschin C (2009) The biology of PGC-1alpha and its therapeutic potential. Trends Pharmacol Sci 30:322–329
Hester SD, Wolf DC, Nesnow S, Thai SF (2006) Transcriptional profiles in liver from rats treated with tumorigenic and non-tumorigenic triazole conazole fungicides: propiconazole, triadimefon, and myclobutanil. Toxicol Pathol 34:879–894
Hester S, Moore T, Padgett WT, Murphy L, Wood CE, Nesnow S (2012) The hepatocarcinogenic conazoles: cyproconazole, epoxiconazole, and propiconazole induce a common set of toxicological and transcriptional responses. Toxicol Sci 127:54–65
IARC (2001) Phenobarbital and its sodium salt, vol 79. IARC Press. IARC Monographs, Lyon, pp 161–288
Jacobsen PR, Axelstad M, Boberg J, Isling LK, Christiansen S, Mandrup KR, Berthelsen LO, Vinggaard AM, Hass U (2012) Persistent developmental toxicity in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides. Reprod Toxicol 34:237–250
Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3:e101. doi:10.1371/journal.pbio.0030101
Long M, Laier P, Vinggaard AM, Andersen HR, Lynggaard J, Bonefeld-Jorgensen EC (2003) Effects of currently used pesticides in the AhR-CALUX assay: comparison between the human TV101L and the rat H4IIE cell line. Toxicology 194:77–93
Menegola E, Broccia ML, Di RF, Giavini E (2006) Postulated pathogenic pathway in triazole fungicide induced dysmorphogenic effects. Reprod Toxicol 22:186–195
Myers JP, vom Saal FS, Akingbemi BT, Arizono K, Belcher S, Colborn T, Chahoud I, Crain DA, Farabollini F, Guillette LJ Jr, Hassold T, Ho SM, Hunt PA, Iguchi T, Jobling S, Kanno J, Laufer H, Marcus M, McLachlan JA, Nadal A, Oehlmann J, Olea N, Palanza P, Parmigiani S, Rubin BS, Schoenfelder G, Sonnenschein C, Soto AM, Talsness CE, Taylor JA, Vandenberg LN, Vandenbergh JG, Vogel S, Watson CS, Welshons WV, Zoeller RT (2009) Why public health agencies cannot depend on good laboratory practices as a criterion for selecting data: the case of bisphenol A. Environ Health Perspect 117:309–315
Nesnow S, Ward W, Moore T, Ren H, Hester SD (2009) Discrimination of tumorigenic triazole conazoles from phenobarbital by transcriptional analyses of mouse liver gene expression. Toxicol Sci 110:68–83
OECD (2013) Guidance document on developing and assessing adverse outcome pathways. Series on testing and assessment 184. OECD, OECD Environment, Health and Safety Publications, Paris
Peffer RC, Moggs JG, Pastoor T, Currie RA, Wright J, Milburn G, Waechter F, Rusyn I (2007) Mouse liver effects of cyproconazole, a triazole fungicide: role of the constitutive androstane receptor. Toxicol Sci 99:315–325
Rhomberg LR, Goodman JE (2012) Low-dose effects and nonmonotonic dose-responses of endocrine disrupting chemicals: has the case been made? Regul Toxicol Pharmacol 64:130–133
SA EF (2010) Conclusion on the peer review of the pesticide risk assessment of the active substance cyproconazole. EFSA J 8(11):1897
SA EF (2011) Conclusion on the peer review of the risk assessment of the active substance prochloraz. EFSA J 9(7):2323
Sun G, Thai SF, Tully DB, Lambert GR, Goetz AK, Wolf DC, Dix DJ, Nesnow S (2005) Propiconazole-induced cytochrome P450 gene expression and enzymatic activities in rat and mouse liver. Toxicol Lett 155:277–287
Sun G, Grindstaff RD, Thai SF, Lambert GR, Tully DB, Dix DJ, Nesnow S (2007) Induction of cytochrome P450 enzymes in rat liver by two conazoles, myclobutanil and triadimefon. Xenobiotica 37:180–193
Tamura K, Inoue K, Takahashi M, Matsuo S, Irie K, Kodama Y, Ozawa S, Nishikawa A, Yoshida M (2013) Dose-response involvement of constitutive androstane receptor in mouse liver hypertrophy induced by triazole fungicides. Toxicol Lett 221:47–56
Trosken ER, Scholz K, Lutz RW, Volkel W, Zarn JA, Lutz WK (2004) Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res 30:387–394
Trosken ER, Adamska M, Arand M, Zarn JA, Patten C, Volkel W, Lutz WK (2006) Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles. Toxicology 228:24–32
Tully DB, Bao W, Goetz AK, Blystone CR, Ren H, Schmid JE, Strader LF, Wood CR, Best DS, Narotsky MG, Wolf DC, Rockett JC, Dix DJ (2006) Gene expression profiling in liver and testis of rats to characterize the toxicity of triazole fungicides. Toxicol Appl Pharmacol 215:260–273
Vanden Bossche H, Willemsens G, Janssen PA (1988) Cytochrome-P-450-dependent metabolism of retinoic acid in rat skin microsomes: inhibition by ketoconazole. Skin Pharmacol 1:176–185
Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr, Lee DH, Shioda T, Soto AM, vom Saal FS, Welshons WV, Zoeller RT, Myers JP (2012) Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev 33:378–455
Vinken M (2013) The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312:158–165
Ward WO, Delker DA, Hester SD, Thai SF, Wolf DC, Allen JW, Nesnow S (2006) Transcriptional profiles in liver from mice treated with hepatotumorigenic and nonhepatotumorigenic triazole conazole fungicides: propiconazole, triadimefon, and myclobutanil. Toxicol Pathol 34:863–878
Wolf DC, Allen JW, George MH, Hester SD, Sun G, Moore T, Thai SF, Delker D, Winkfield E, Leavitt S, Nelson G, Roop BC, Jones C, Thibodeaux J, Nesnow S (2006) Toxicity profiles in rats treated with tumorigenic and nontumorigenic triazole conazole fungicides: propiconazole, triadimefon, and myclobutanil. Toxicol Pathol 34:895–902
Zarn JA, Bruschweiler BJ, Schlatter JR (2003) Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. Environ Health Perspect 111:255–261
Acknowledgments
We thank Daniela Neubert, Sabine Krönke, Barbara Freytag and Brigitte Ladwig for excellent technical assistance and Matthias Peiser for the critical revision of the manuscript.
Conflict of interest
The authors do not have any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Heise, T., Schmidt, F., Knebel, C. et al. Hepatotoxic effects of (tri)azole fungicides in a broad dose range. Arch Toxicol 89, 2105–2117 (2015). https://doi.org/10.1007/s00204-014-1336-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-014-1336-1